Algert Global LLC Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Algert Global LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,900 shares of the biopharmaceutical company’s stock, valued at approximately $521,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Fiduciary Alliance LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth about $398,000. Tealwood Asset Management Inc. increased its holdings in Halozyme Therapeutics by 19.7% during the 4th quarter. Tealwood Asset Management Inc. now owns 52,813 shares of the biopharmaceutical company’s stock worth $2,525,000 after purchasing an additional 8,694 shares during the period. Park Avenue Securities LLC increased its holdings in Halozyme Therapeutics by 6.9% during the 4th quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company’s stock worth $595,000 after purchasing an additional 801 shares during the period. Redhawk Wealth Advisors Inc. increased its holdings in Halozyme Therapeutics by 3.4% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 38,035 shares of the biopharmaceutical company’s stock worth $1,818,000 after purchasing an additional 1,267 shares during the period. Finally, Outlook Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth about $355,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Finally, Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 7th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $63.78.

Halozyme Therapeutics Trading Down 2.8%

NASDAQ:HALO opened at $65.86 on Monday. The stock has a 50-day simple moving average of $61.45 and a 200-day simple moving average of $55.88. The stock has a market cap of $8.14 billion, a P/E ratio of 19.20, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to analysts’ expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business’s revenue was up 35.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.79 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company’s stock, valued at $2,120,567.40. This represents a 1.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This trade represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,697 shares of company stock valued at $1,276,552 in the last three months. 2.90% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.